Dova Pharmaceuticals Inc. appointed David Zaccardelli president and CEO, and also named Jason Hoitt chief commercial officer.
Zaccardelli — who was previously acting CEO of Cempra Pharmaceuticals Inc. until the company's merger with Melinta Therapeutics Inc. — is replacing Alex Sapir in the president and CEO roles.
Hoitt was previously vice president and head of U.S. sales at Insmed Inc. and head of U.S. sales and senior director of medical affairs at Sarepta Therapeutics Inc.
Dova expects the appointments of Zaccardelli and Hoitt to accelerate the launch of the company's bleeding disorder drug Doptelet. The therapy was approved by the U.S. Food and Drug Administration in May to treat thrombocytopenia, a condition characterized by an abnormally low platelet count, in adults with chronic liver disease.
Dova is also seeking the U.S. FDA's approval for Doptelet as a therapy for immune thrombocytopenia, a bleeding disorder that can lead to excessive bruising and bleeding due to low levels of platelets in the blood.